The stock of TrovaGene, Inc. (NASDAQ:TROV) has been Initiated to Buy by H.C. Wainwright in its latest research note that was published on December 21. TROV was given a price target of $1, with other Wall Street analysts also giving their reports regarding the stock. Maxim Group analysts have downgraded their rating of TROV stock from Buy to Hold in a separate flash note to investors on November 10. Analysts at Maxim Group issued an upgrade fromHold to Buy for the stock, in a research note that dated back to April 12.
TrovaGene,’s stock is covered by 2 analysts, with none of them rating the stock as Buy. It has been deemed to have strong buy by 2 of the analysts, none of them have rated it as a Hold while none of them rated it as sell. The situation was different a month ago when the stock was rated as a Buy by only none analysts. 2 of them rated it as strong buy with none of them recommended investors to Hold on to the stock. Meanwhile, none analyst(s) rated it as a sell. The above data shows that TROV has an average analyst rating of 2.00.
TrovaGene, Inc., which has current market capitalization of above $8 Million, published its last quarter earnings on March 31, 2019. The company was able to amass $0.16 million in revenue. This figure is $0.01 million more than what analysts had expected which was $0.17 million. During the first quarter of the year, TrovaGene, also recorded $-1.02 earnings per share (EPS) which is $0.05 above the $-1.07 estimated by Thomson Reuter’s analyst, leading to a surprise factor of -4.67%.
TROV declined by $-0.01 during the normal trading session on Tuesday and reaching a high of $1.66 during the day while it closed the day at $1.53. The TrovaGene, stock had a low trading volume of 0.13 million shares on that day, which is low compared to the average daily volume of 82.61M shares. TROV has also lost 7.27% of its value over the past 7 days. However, the stock has declined by 51.58% in the 3 months of the year. Over the past six months meanwhile, it has lost 55.26% while it has lost 51.47% year-on date. Let us now take a look at the stock’s potential support and resistance levels. The publicly traded company was seen to have slipped by -55.78% from its 3 months high price. However, taking another look at TROV will indicate that it is trading +2% away from its 90-day low. Looking at the bigger picture, the TrovaGene, Inc. stock has dropped by -84.15% from its 52-week high while it has surged by +2% from its 52-week low price.
On June 20, 2018 Markin Rodney S, Director bought 6866.68 shares of the company. The average price for that transaction was $5.1 per share, which meant that Markin Rodney S spent $35020.07 purchasing the stocks. The purchase was made public, with the document of the transaction filed with the SEC. Another insider trading occurred, with Director, Markin Rodney S purchasing 6866.68 shares of this stock on June 20, 2018. The average purchasing price for the stock was $5.1 per share, with the purchased stock accruing $35020.07. Following this transaction, the Director Markin Rodney S now holds 19708 shares of the company, which is worth around $32912.36.
TrovaGene, has around 11 Billion cash on their books at the moment. This figure will have to be compared and looked into, with their current liabilities standing at $4 Billion. The TrovaGene, stock is bringing in revenue of over 12 months, which is roughly 138 Million. Despite all that, TrovaGene, Inc. is seeing things progressing very much as their y-o-y quarterly revenue surged by 23.21%.
Looking at the stock’s Technical analysis information over the past 50 days shows that its Raw Stochastic average stood at 1.53%. This figure is worse than the company’s 20-day Raw Stochastic average which currently stands at 4.11%. Over the past 20 days, TrovaGene,’s Stochastic %K stood at 6.58% while its Stochastic %D was revealed to be 8.04%.